Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

Performance of Contactless Respiratory Rate Monitoring by Albus HomeTM, an Automated System for Nocturnal Monitoring at Home: A Validation Study

Do W. et al, (2022), Sensors, 22, 7142 - 7142

Performance of cough monitoring by Albus Home™, a contactless and automated system for nocturnal respiratory monitoring at home

Do W. et al, (2022), ERJ Open Research, 00265 - 2022

Early Th2 inflammation in the upper respiratory mucosa as a predictor of severe COVID-19 and modulation by early treatment with inhaled corticosteroids: a mechanistic analysis

Baker JR. et al, (2022), The Lancet Respiratory Medicine, 10, 545 - 556

Discordant diagnostic criteria for pneumonia in COPD trials: a review

Wise RA. et al, (2021), European Respiratory Review, 30, 210124 - 210124

Dampening of the respiratory cytokine storm is promoted by inhaled budesonide in patients with early COVID-19

Baker JR. et al, (2021)

A new piece in the puzzle: the eosinophil and the development of COPD

Petousi N. et al, (2021), European Respiratory Journal, 58, 2101105 - 2101105

Renaming COPD exacerbations: the UK respiratory nursing perspective.

Mwasuku C. et al, (2021), BMC pulmonary medicine, 21

Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial

Yu L-M. et al, (2021), The Lancet, 398, 843 - 855

Predicting treatment outcomes following an exacerbation of airways disease

Halner A. et al, (2021), PLOS ONE, 16, e0254425 - e0254425

Inhaled budesonide for COVID-19 in people at higher risk of adverse outcomes in the community: interim analyses from the PRINCIPLE trial

Yu L-M. et al, (2021)

Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial

Ramakrishnan S. et al, (2021), The Lancet Respiratory Medicine

30-day readmission after an acute exacerbation of chronic obstructive pulmonary disease is associated with cardiovascular comorbidity

Alpaydin AO. et al, (2021), Turkish Thoracic Journal, 22, 369 - 375

Finding the true prevalence of obstructive lung disease: two steps forward and one step back

Russell REK. and Wang K., (2020), European Respiratory Journal, 55, 2001514 - 2001514

The Use of Benralizumab in the Treatment of Near-Fatal Asthma: A New Approach

Ramakrishnan S. et al, (2020), American Journal of Respiratory and Critical Care Medicine, 201, 1441 - 1443

Chronic obstructive pulmonary disease: management of chronic disease

Ramakrishnan S. et al, (2020), Medicine, 48, 333 - 336

Evaluating the sensitivity and specificity of NEATstik technology compared to an activity-based immunoassay in sputum samples from participants with COPD

Thulborn SJ. et al, (2020), European Respiratory Journal, 55, 1902412 - 1902412

Covid-19 and COPD: A Personal Reflection

Russell R., (2020), International Journal of Chronic Obstructive Pulmonary Disease, Volume 15, 883 - 884

Exacerbations of chronic obstructive pulmonary disease: time to rename.

Bafadhel M. et al, (2020), The Lancet. Respiratory medicine, 8, 133 - 135

“Breathing New Life Into Chronic Obstructive Pulmonary Disease (COPD)” – Results From An Online Survey Of UK Patients

Titmarsh S. et al, (2019), International Journal of Chronic Obstructive Pulmonary Disease, Volume 14, 2799 - 2807

In the race at last: post-hoc analysis of GALATHEA and TERRANOVA.

Ramakrishnan S. and Russell R., (2019), The Lancet. Respiratory medicine

Load More

Include forthcoming?